Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice

Gastroenterology

Volumn 152, Issue 5, 2017, Pages 1161-1173.e1

  Song, Chun Qing ^a   Li, Yingxiang ^a,b   Mou, Haiwei ^a   Moore, Jill ^a   Park, Angela ^a   Pomyen, Yotsawat ^c   Hough, Soren ^a   Kennedy, Zachary ^a   Fischer, Andrew ^a   Yin, Hao ^d   Anderson, Daniel G ^d,e   Conte, Darryl ^a   Zender, Lars ^f,g   Wang, Xin Wei ^c   Thorgeirsson, Snorri ^c   Weng, Zhiping ^a,b   Xue, Wen ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b TONGJI UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

CRISPR Screen; Liver Cancer; Mouse Model; Tumor Suppressor Genes

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B9D1 PROTEIN; FLRT2 PROTEIN; GUIDE RNA; HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NF1 PROTEIN; PLXNB1 PROTEIN; PROTEIN P53; RAS PROTEIN; SELUMETINIB; SHORT HAIRPIN RNA; SORAFENIB; TRAMETINIB; TRANSCRIPTION FACTOR SOX9; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; B9D1 PROTEIN, MOUSE; BENZIMIDAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CELL SURFACE RECEPTOR; DNA; ENZYME INHIBITOR; FLRT2 PROTEIN, MOUSE; HIGH MOBILITY GROUP A PROTEIN; MEMBRANE PROTEIN; MYC PROTEIN; NERVE PROTEIN; NICOTINAMIDE; NITRILE; PLXNB1 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LIBRARY; GENE LOSS; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC SCREENING; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SEQUENCING; HISTOLOGY; HUMAN; HUMAN CELL; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; LENTIVIRINAE; LIVER CANCER CELL LINE; LIVER CELL; LIVER FUNCTION; LIVER TISSUE; LIVER TUMOR; MOUSE; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CRISPR CAS SYSTEM; DNA SEQUENCE; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; METABOLISM; NUDE MOUSE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; BUTADIENES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; DNA, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEUROFIBROMATOSIS 1; GENOME-WIDE ASSOCIATION STUDY; HEPATOCYTES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HMGA PROTEINS; HMGA2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE TISSUE PROTEINS; NIACINAMIDE; NITRILES; PHENYLUREA COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDONES; PYRIMIDINONES; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 85016206133     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.12.002     Document Type: Article

References (57)

1. 1 Zucman-Rossi, J., Villanueva, A., Nault, J.C., et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149 (2015), 1226–1239.
2. 2 Farazi, P.A., DePinho, R.A., Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006), 674–687.
3. 3 Marquardt, J.U., Andersen, J.B., Thorgeirsson, S.S., Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer 15 (2015), 653–667.
4. 4 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. Cancer 65 (2015), 87–108.
5. 5 Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
6. 6 Totoki, Y., Tatsuno, K., Covington, K.R., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46 (2014), 1267–1273.
7. 7 Keng, V.W., Villanueva, A., Chiang, D.Y., et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 27 (2009), 264–274.
8. 8 O'Donnell, K.A., Keng, V.W., York, B., et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A 109 (2012), E1377–E1386.
9. 9 Bard-Chapeau, E.A., Nguyen, A.T., Rust, A.G., et al. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet 46 (2014), 24–32.
10. 10 Ranzani, M., Cesana, D., Bartholomae, C.C., et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 10 (2013), 155–161.
11. 11 Zender, L., Xue, W., Zuber, J., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008), 852–864.
12. 12 Rudalska, R., Dauch, D., Longerich, T., et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20 (2014), 1138–1146.
13. 13 Wuestefeld, T., Pesic, M., Rudalska, R., et al. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 153 (2013), 389–401.
14. 14 Doudna, J.A., Charpentier, E., The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
15. 15 Xue, W., Chen, S., Yin, H., et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514 (2014), 380–385.
16. 16 Yin, H., Xue, W., Chen, S., et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32 (2014), 551–553.
17. 17 Wang, D., Mou, H., Li, S., et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 26 (2015), 432–442.
18. 18 Yin, H., Song, C.-Q., Dorkin, J.R., et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotech 34 (2016), 328–333.
19. 19 Weber, J., Ollinger, R., Friedrich, M., et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci U S A 112 (2015), 13982–13987.
20. 20 Shalem, O., Sanjana, N.E., Hartenian, E., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:6166 (2014), 84–87.
21. 21 Wang, T., Wei, J.J., Sabatini, D.M., et al. Genetic screens in human cells using the CRISPR/Cas9 system. Science 343:6166 (2014), 80–84.
22. 22 Chen, S., Sanjana, N.E., Zheng, K., et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160 (2015), 1246–1260.
23. 23 Sanjana, N.E., Shalem, O., Zhang, F., Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11 (2014), 783–784.
24. 24 Cong, L., Ran, F.A., Cox, D., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
25. 25 Li, Y., Park, A., Mou, H., et al. A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biol, 16, 2015, 111.
26. 26 Zender, L., Spector, M.S., Xue, W., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006), 1253–1267.
27. 27 Katz, S.F., Lechel, A., Obenauf, A.C., et al. Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology 142 (2012), 1229–1239.
28. 28 Saborowski, A., Saborowski, M., Davare, M.A., et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A 110 (2013), 19513–19518.
29. 29 Langmead, B., Trapnell, C., Pop, M., et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol, 10, 2009, R25.
30. 30 Shao, D.D., Xue, W., Krall, E.B., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158 (2014), 171–184.
31. 31 Anders, S., Huber, W., Differential expression analysis for sequence count data. Genome Biol, 11, 2010, R106.
32. 32 Lee, J.S., Chu, I.S., Mikaelyan, A., et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36 (2004), 1306–1311.
33. 33 Weinstein, J.N., Collisson, E.A., Mills, G.B., et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45 (2013), 1113–1120.
34. 34 Thorgeirsson, S.S., Grisham, J.W., Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31 (2002), 339–346.
35. 35 Ratner, N., Miller, S.J., A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15 (2015), 290–301.
36. 36 Czabotar, P.E., Lessene, G., Strasser, A., et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15 (2014), 49–63.
37. 37 Gomez Roman, J.J., Garay, G.O., Saenz, P., et al. Plexin B1 is downregulated in renal cell carcinomas and modulates cell growth. Transl Res 151 (2008), 134–140.
38. 38 Shi, J., Wang, E., Milazzo, J.P., et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 33 (2015), 661–667.
39. 39 Forbes, S.A., Beare, D., Gunasekaran, P., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (2014), D805–D811.
40. 40 Delire, B., Starkel, P., The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest 45 (2015), 609–623.
41. 41 Calvisi, D.F., Ladu, S., Conner, E.A., et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 54 (2011), 311–319.
42. 42 Calvisi, D.F., Ladu, S., Gorden, A., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006), 1117–1128.
43. 43 Ito, Y., Sasaki, Y., Horimoto, M., et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27 (1998), 951–958.
44. 44 Li, C., Wu, X., Zhang, W., et al. AEG-1 Promotes metastasis through downstream AKR1C2 and NF1 in liver cancer. Oncol Res 22 (2014), 203–211.
45. 45 Huang, C.H., Lujambio, A., Zuber, J., et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28 (2014), 1800–1814.
46. 46 Moon, R.T., Kohn, A.D., De Ferrari, G.V., et al. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5 (2004), 691–701.
47. 47 Fusco, A., Fedele, M., Roles of HMGA proteins in cancer. Nat Rev Cancer 7 (2007), 899–910.
48. 48 Xue, W., Zender, L., Miething, C., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007), 656–660.
49. 49 Winslow, M.M., Dayton, T.L., Verhaak, R.G., et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473 (2011), 101–104.
50. 50 Breunig, C., Mueller, B.J., Umansky, L., et al. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma. Clin Cancer Res 20 (2014), 2410–2423.
51. 51 Roessler, S., Long, E.L., Budhu, A., et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142 (2012), 957–966. e12.
52. 52 Lee, J.S., Heo, J., Libbrecht, L., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 (2006), 410–416.
53. 53 Tabernero, J., Shapiro, G.I., Lorusso, P.M., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3 (2013), 406–417.
54. 54 Oinuma, I., Ishikawa, Y., Katoh, H., et al. The semaphorin 4D receptor plexin-B1 is a GTPase activating protein for R-Ras. Science 305 (2004), 862–865.
55. 55 Haines, B.P., Wheldon, L.M., Summerbell, D., et al. Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development. Dev Biol 297 (2006), 14–25.
56. 56 Kodama, T., Bard-Chapeau, E.A., Newberg, J.Y., et al. Two-step forward genetic screen in mice identifies Ral GTPase-activating proteins as suppressors of hepatocellular carcinoma. Gastroenterology 151 (2016), 324–337.e12.
57. 57 Sanchez-Rivera, F.J., Jacks, T., Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15 (2015), 387–395.